دورية أكاديمية
أعرض في EDS

Physalis Mottle Virus-Like Particles as Nanocarriers for Imaging Reagents and Drugs.

التفاصيل البيبلوغرافية
العنوان: Physalis Mottle Virus-Like Particles as Nanocarriers for Imaging Reagents and Drugs.
المؤلفون: Masarapu H; Department of Virology, Sri Venkateswara University , Tirupati, 517 502 Andhra Pradesh, India., Patel BK, Chariou PL, Hu H, Gulati NM, Carpenter BL; Department of Chemistry, North Carolina State University , Raleigh, North Carolina 27695, United States., Ghiladi RA; Department of Chemistry, North Carolina State University , Raleigh, North Carolina 27695, United States., Shukla S, Steinmetz NF
المصدر: Biomacromolecules [Biomacromolecules] 2017 Dec 11; Vol. 18 (12), pp. 4141-4153. Date of Electronic Publication: 2017 Nov 16.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 100892849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1526-4602 (Electronic) Linking ISSN: 15257797 NLM ISO Abbreviation: Biomacromolecules Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : American Chemical Society, c2000-
مواضيع طبية MeSH: Drug Carriers/*chemistry , Indicators and Reagents/*chemistry , Nanoparticles/*chemistry , Pharmaceutical Preparations/*chemistry , Tymovirus/*chemistry, Animals ; Cell Line ; Cell Line, Tumor ; Doxorubicin/chemistry ; HeLa Cells ; Humans ; Lysine/chemistry ; Maleimides/chemistry ; Mice ; Mitoxantrone/chemistry ; Neoplasms/diagnosis ; Neoplasms/diagnostic imaging ; Photosensitizing Agents/chemistry ; RAW 264.7 Cells
مستخلص: Platform technologies based on plant virus nanoparticles (VNPs) and virus-like particles (VLPs) are attracting the attention of researchers and clinicians because the particles are biocompatible, biodegradable, noninfectious in mammals, and can readily be chemically and genetically engineered to carry imaging agents and drugs. When the Physalis mottle virus (PhMV) coat protein is expressed in Escherichia coli, the resulting VLPs are nearly identical to the viruses formed in vivo. Here, we isolated PhMV-derived VLPs from ClearColi cells and carried out external and internal surface modification with fluorophores using reactive lysine-N-hydroxysuccinimide ester and cysteine-maleimide chemistries, respectively. The uptake of dye-labeled particles was tested in a range of cancer cells and monitored by confocal microscopy and flow cytometry. VLPs labeled internally on cysteine residues were taken up with high efficiency by several cancer cell lines and were colocalized with the endolysosomal marker LAMP-1 within 6 h, whereas VLPs labeled externally on lysine residues were taken up with lower efficiency, probably reflecting differences in surface charge and the propensity to bind to the cell surface. The infusion of dye and drug molecules into the cavity of the VLPs revealed that the photosensitizer (PS), Zn-EpPor, and the drugs crystal violet, mitoxantrone (MTX), and doxorubicin (DOX) associated stably with the carrier via noncovalent interactions. We confirmed the cytotoxicity of the PS-PhMV and DOX-PhMV particles against prostate cancer, ovarian and breast cancer cell lines, respectively. Our results show that PhMV-derived VLPs provide a new platform technology for the delivery of imaging agents and drugs, with preferential uptake into cancer cells. These particles could therefore be developed as multifunctional tools for cancer diagnosis and therapy.
References: J Control Release. 2016 Jun 10;231:103-13. (PMID: 26941034)
Adv Drug Deliv Rev. 2017 Jan 1;108:25-38. (PMID: 27137110)
Annu Rev Phytopathol. 2008;46:361-84. (PMID: 18473700)
Vaccine. 2009 Dec 10;28(1):132-9. (PMID: 19818723)
Prog Nucleic Acid Res Mol Biol. 2005;80:135-68. (PMID: 16164974)
ACS Biomater Sci Eng. 2016 May 9;2(5):838-844. (PMID: 28713855)
Vaccines (Basel). 2015 Aug 05;3(3):620-37. (PMID: 26350598)
Pol J Microbiol. 2015;64(1):3-13. (PMID: 26094310)
Curr Opin Virol. 2016 Jun;18:44-9. (PMID: 27039982)
ACS Nano. 2010 Oct 26;4(10):6014-20. (PMID: 20863095)
Curr Opin Biotechnol. 2011 Dec;22(6):901-8. (PMID: 21592772)
Biomacromolecules. 2012 Dec 10;13(12 ):3990-4001. (PMID: 23121655)
Trends Microbiol. 2003 Sep;11(9):438-44. (PMID: 13678860)
Bioconjug Chem. 2011 Jan 19;22(1):67-73. (PMID: 21126069)
Arch Virol. 1992;123(3-4):367-77. (PMID: 1562236)
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Jul;9(4):. (PMID: 28078770)
Chem Commun (Camb). 2008 Jan 7;(1):88-90. (PMID: 18401897)
Bioconjug Chem. 2007 May-Jun;18(3):836-43. (PMID: 17407258)
Acta Biochim Pol. 2016;63(3):469-73. (PMID: 27474402)
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 Sep-Oct;7(5):708-21. (PMID: 25683790)
Biomaterials. 2013 Jun;34(19):4632-42. (PMID: 23528229)
J Mol Biol. 1999 Jun 18;289(4):905-18. (PMID: 10369771)
Curr Opin Struct Biol. 2017 Apr;43:148-155. (PMID: 28359961)
J Mol Biol. 1999 Jun 18;289(4):919-34. (PMID: 10369772)
Biopolymers. 2016 Mar;105(3):113-32. (PMID: 26509554)
Mol Pharm. 2011 Feb 7;8(1):29-43. (PMID: 21047140)
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Jul;8(4):554-78. (PMID: 26782096)
Annu Rev Pharmacol Toxicol. 2009;49:303-26. (PMID: 18851703)
Annu Rev Virol. 2015 Nov;2(1):379-401. (PMID: 26958921)
Biotechnol Bioeng. 2014 Mar;111(3):425-40. (PMID: 24347238)
Bioconjug Chem. 2011 Mar 16;22(3):346-52. (PMID: 21338097)
Pharm Res. 2010 Nov;27(11):2509-13. (PMID: 20811934)
Adv Exp Med Biol. 2016;940:83-120. (PMID: 27677510)
PLoS One. 2010 Mar 22;5(3):e9784. (PMID: 20339535)
BMC Biotechnol. 2015 Aug 27;15:80. (PMID: 26311254)
Protein Expr Purif. 2015 Sep;113:35-43. (PMID: 25959459)
Chem Soc Rev. 2016 Jul 25;45(15):4074-126. (PMID: 27152673)
Adv Drug Deliv Rev. 2012 Jun 15;64(9):811-25. (PMID: 22285585)
Mol Biotechnol. 2013 Jan;53(1):92-107. (PMID: 23001867)
Bioconjug Chem. 2015 Jan 21;26(1):51-62. (PMID: 25541212)
J Virol Methods. 2011 Dec;178(1-2):209-15. (PMID: 21963393)
ACS Nano. 2011 Feb 22;5(2):1243-52. (PMID: 21210643)
NPJ Vaccines. 2017 Feb 9;2:3. (PMID: 29263864)
Arch Virol. 2006 Oct;151(10):1917-31. (PMID: 16732495)
Oncotarget. 2017 May 2;8(18):30524-30538. (PMID: 28430624)
Virology. 2015 May;479-480:200-12. (PMID: 25816763)
J Biomed Opt. 2011 Feb;16(2):026002. (PMID: 21361686)
J Gen Virol. 2006 Sep;87(Pt 9):2749-54. (PMID: 16894216)
Methods. 2006 Sep;40(1):60-5. (PMID: 16997714)
Nat Med. 2006 Mar;12(3):354-60. (PMID: 16501571)
Arch Virol. 1998;143(8):1489-500. (PMID: 9739328)
Mol Pharm. 2013 Jan 7;10(1):3-10. (PMID: 22827473)
Bioeng Transl Med. 2017 Jan 19;2(1):43-57. (PMID: 29313023)
Curr Opin Biotechnol. 2007 Dec;18(6):537-45. (PMID: 18083549)
Chem Soc Rev. 2012 Sep 21;41(18):6178-94. (PMID: 22880206)
J Mol Biol. 2001 Apr 6;307(4):1035-47. (PMID: 11286554)
Intervirology. 2013;56(3):141-65. (PMID: 23594863)
Biomacromolecules. 2012 Aug 13;13(8):2333-8. (PMID: 22827531)
Curr Opin Biotechnol. 2016 Feb;37:201-206. (PMID: 26773389)
Bioconjug Chem. 2016 May 18;27(5):1227-35. (PMID: 27077475)
Curr Opin Chem Biol. 2017 Jun;38:108-116. (PMID: 28426952)
J Mol Biol. 1997 Oct 3;272(4):541-52. (PMID: 9325111)
Sci Rep. 2016 Nov 24;6:37891. (PMID: 27883070)
Nanoscale. 2017 Feb 9;9(6):2348-2357. (PMID: 28144662)
Appl Microbiol Biotechnol. 2014 Mar;98(5):1963-70. (PMID: 24407451)
Lett Appl Microbiol. 2017 Feb;64(2):111-123. (PMID: 27859400)
PLoS Pathog. 2009 May;5(5):e1000417. (PMID: 19412526)
Vaccine. 2007 Jun 15;25(25):4784-94. (PMID: 17499404)
Sci Rep. 2016 Feb 24;6:21803. (PMID: 26905902)
J Am Chem Soc. 2004 Jan 14;126(1):301-10. (PMID: 14709096)
Pharm Res. 2015 Nov;32(11):3699-707. (PMID: 26047779)
Curr Top Microbiol Immunol. 2014;375:61-87. (PMID: 22038411)
J Gen Virol. 2012 May;93(Pt 5):1120-6. (PMID: 22278829)
ACS Nano. 2017 May 23;11(5):4719-4730. (PMID: 28345874)
Curr Opin Biotechnol. 2014 Aug;28:75-82. (PMID: 24832078)
PLoS One. 2012;7(8):e43814. (PMID: 22937101)
معلومات مُعتمدة: R01 CA202814 United States CA NCI NIH HHS
المشرفين على المادة: 0 (Drug Carriers)
0 (Indicators and Reagents)
0 (Maleimides)
0 (Pharmaceutical Preparations)
0 (Photosensitizing Agents)
2519R1UGP8 (maleimide)
80168379AG (Doxorubicin)
BZ114NVM5P (Mitoxantrone)
K3Z4F929H6 (Lysine)
SCR Organism: Physalis mottle virus
تواريخ الأحداث: Date Created: 20171117 Date Completed: 20180716 Latest Revision: 20181113
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC5922981
DOI: 10.1021/acs.biomac.7b01196
PMID: 29144726
قاعدة البيانات: MEDLINE
الوصف
تدمد:1526-4602
DOI:10.1021/acs.biomac.7b01196